Marico Limited
Acquisition
01 / The disclosure
What the company shared
Please find attached an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
A question for your research
Check transaction size, funding, dilution, approvals and completion conditions before assessing the earnings impact.
Numbers found in document text 5 matches
Automatic text matches, not verified financial metrics. A match may come from a table heading or reporting year. Expand it to inspect the surrounding text and original page.
60%Page 1
October 5, 2026 Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) We refer to our letters dated July 26, 2023, November 30, 2023, May 31, 2025 and December 17, 2025, informing that Marico Limited (“Company”/”Marico”) has acquired an aggregate of 60% stake on a fully diluted basis in Satiya Nutraceuticals Private Limited (“ Satiya Nutraceuticals ”), a subsidiary that owns the brand “ PLIX”, and further has a right under the definitive agreement(s) to acquire the remaining 40% stake, subject to certain terms and conditions.
View source page40%Page 1
October 5, 2026 Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) We refer to our letters dated July 26, 2023, November 30, 2023, May 31, 2025 and December 17, 2025, informing that Marico Limited (“Company”/”Marico”) has acquired an aggregate of 60% stake on a fully diluted basis in Satiya Nutraceuticals Private Limited (“ Satiya Nutraceuticals ”), a subsidiary that owns the brand “ PLIX”, and further has a right under the definitive agreement(s) to acquire the remaining 40% stake, subject to certain terms and conditions.
View source page38.18%Page 1
Pursuant to the above, the Company has entered into definitive agreement(s) to acquire 38.18% stake in Satiya Nutraceuticals on a fully diluted basis, in tranches, from its Founders and certain other shareholders as per terms and conditions agreed therein.
View source page24.09%Page 1
As part of the aforesaid transaction, the Company has currently acquired 24.09% stake in Satiya Nutraceuticals, thereby increasing its aggregate stake from 60% to 84.09% on a fully diluted basis.
View source page84.09%Page 1
As part of the aforesaid transaction, the Company has currently acquired 24.09% stake in Satiya Nutraceuticals, thereby increasing its aggregate stake from 60% to 84.09% on a fully diluted basis.
View source pageThe evidence
Read the source excerpts
01October 5, 2026 Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) We refer to our letters dated July 26, 2023, November 30, 2023, May 31, 2025 and December 17, 2025, informing that Marico Limited (“Company”/”Marico”) has acquired an aggregate of 60% stake on a fully diluted basis in Satiya Nutraceuticals Private Limited (“ Satiya Nutraceuticals ”), a subsidiary that owns the brand “ PLIX”, and further has a right under the definitive agreement(s) to acquire the remaining 40% stake, subject to certain terms and conditions.
Page 1
02Pursuant to the above, the Company has entered into definitive agreement(s) to acquire 38.18% stake in Satiya Nutraceuticals on a fully diluted basis, in tranches, from its Founders and certain other shareholders as per terms and conditions agreed therein.
Page 1
03As part of the aforesaid transaction, the Company has currently acquired 24.09% stake in Satiya Nutraceuticals, thereby increasing its aggregate stake from 60% to 84.09% on a fully diluted basis.
Page 1
04Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sl.
Page 2
05Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/group companies have any interest in the entity being acquired Yes, the acquisition by the Company of stake held by the Founders of Satiya Nutraceuticals and their relatives/related entities are related party transactions, which are on an arm’s length basis.
Page 2
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 106807508
- First collected
- 5 Oct 2026, 21:01 IST
- PDF extraction
- extracted · 2 pages read
- Extraction note
- Source excerpts; financial tables have not been validated.
- Document SHA-256
- 0956924b9a34fe0dc874b9c609d128155dd18e19cf68040c867bbfc06e932d06